Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
12°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xoma Royalty Corporation
(NQ:
XOMA
)
31.01
+0.81 (+2.68%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xoma Royalty Corporation
< Previous
1
2
3
Next >
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
February 16, 2024
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024.
Via
Benzinga
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio
From
XOMA Corporation
Via
GlobeNewswire
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA's Return On Capital Employed Insights
May 24, 2023
Via
Benzinga
XOMA Earnings Perspective: Return On Capital Employed
March 15, 2023
Via
Benzinga
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Stock Repurchase Program of up to $50 Million
January 02, 2024
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023
FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
XOMA Corporation
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
September 01, 2023
On Friday, 57 companies reached new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
August 28, 2023
During Monday, 102 stocks hit new 52-week lows.
Via
Benzinga
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 08, 2023
From
XOMA Corporation
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
During Thursday, 56 stocks hit new 52-week lows.
Via
Benzinga
XOMA Added to the Russell 2000® and Russell 3000® Indexes
June 23, 2023
From
XOMA Corporation
Via
GlobeNewswire
Arimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: Analyst
June 22, 2023
Earlier today, XOMA Corporation (NASDAQ: XOMA) acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol for Niemann-Pick disease type C, and...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
July 26, 2023
Wednesday saw 59 companies set new 52-week lows.
Via
Benzinga
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
June 22, 2023
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2023
From
XOMA Corporation
Via
GlobeNewswire
Recap: XOMA Q1 Earnings
May 09, 2023
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,...
Via
Benzinga
XOMA: Q1 Earnings Insights
May 09, 2023
XOMA (NASDAQ:XOMA) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:30 AM. Here's what investors need to know about the announcement. Earnings XOMA missed estimated earnings by 96.0%,...
Via
Benzinga
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
May 09, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
April 26, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
March 30, 2023
Acquired IXINITY® commercial payment and milestone economics from Aptevo Therapeutics
From
XOMA Corporation
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2023
From
XOMA Corporation
Via
GlobeNewswire
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
March 09, 2023
From
XOMA Corporation
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.